StreetAlpha
13F holdings · Q3 2026

Spruce Street Capital

New York, NY · files as Spruce Street Capital LP
Know the moment Spruce Street Capital filesYou follow Spruce Street Capital An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 13, 2026Next filing due Feb 15, 2027CIK 2050194

Spruce Street Capital reported 39 stocks worth $629M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are KNSA (10.9%), RLAY (8.6%) and LBRX (8.6%). Compared with Q2 2026, the fund opened new positions in ENTX, OBX and SGMT and added to LBRX, ANRO and ALKS.

Latest filing: what Spruce Street Capital did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
9 new8 added0 trimmed0 sold outBought about $162M · sold about $0
New 9
See all 9 →
Added 8
See all 8 →
Trimmed 0

None

Sold out 0

None

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$629M+23.4% vs last quarter
Stocks held399 new · 0 sold out
Top 5 weight40.9%fairly concentrated
Turnover26%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 4 qtrsHeld
1
KNSA
Kiniksa Pharmaceuticals Intl
$68.5M10.9%918KNo change4 of 4
2
RLAY
Relay Therapeutics Inc
$53.9M8.6%3MNo change4 of 4
3
LBRX
LB Pharmaceuticals Inc
$53.9M8.6%1.4M+29K (+2%)4 of 4
4
ANRO
Alto Neuroscience Inc
$42.8M6.8%1.7M+324K (+24%)4 of 4
5
ALKS
Alkermes PLC
$38.4M6.1%948K+405K (+74%)3 of 4
6
ENTX
Entera Bio Ltd
$32.6M5.2%11.2MNew position1 of 4
7
DNTH
Dianthus Therapeutics Inc
$31.2M5.0%355KNo change4 of 4
8
SVRA
Savara Inc
$27.8M4.4%5.4M+1.9M (+56%)4 of 4
9
ZLAB
Zai Lab Ltd
$27.5M4.4%1M+763K (+273%)2 of 4
10
RLMD
Relmada Therapeutics Inc
$26.1M4.1%6.9M+521K (+8%)4 of 4
🔒 29 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Reported value

last 4 quarters
$303MQ4 '25
$416MQ1 '26
$510MQ2 '26
$629MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 13, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Spruce Street Capital 13F FAQ

What does Spruce Street Capital own?

Spruce Street Capital reported 39 stocks worth $629M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are KNSA (10.9%), RLAY (8.6%) and LBRX (8.6%). The table above lists every position in the filing (the top 10 without an account).

What did Spruce Street Capital buy and sell in Q3 2026?

Compared with Q2 2026: 9 new positions, 8 added to, 0 trimmed and 0 sold out. New positions include ENTX, OBX and SGMT.

When will Spruce Street Capital file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Spruce Street Capital's portfolio worth?

The Q3 2026 filing reports $629M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.